Magyar
Toggle navigation
Tudóstér
Magyar
Tudóstér
Keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Egyszerű keresés
Összetett keresés
CCL keresés
Böngészés
Saját polc tartalma
(
0
)
Korábbi keresések
CCL parancs
CCL
Összesen 3 találat.
#/oldal:
12
36
60
120
Rövid
Hosszú
MARC
Részletezés:
Rendezés:
Szerző növekvő
Szerző csökkenő
Cím növekvő
Cím csökkenő
Dátum növekvő
Dátum csökkenő
1.
001-es BibID:
BIBFORM012817
Első szerző:
Muszbek László (haematológus, kutató orvos)
Cím:
Factor XIII and Atherothrombotic Diseases / Muszbek László, Bereczky Zsuzsanna, Bagoly Zsuzsa, Shemirani Amir-Houshang, Katona Éva
Dátum:
2010
ISSN:
0094-6176
Megjegyzések:
Factor XIII (FXIII) is a protransglutaminase that, after activation, cross-links fibrin chains and several plasma proteins, most importantly 2 plasmin inhibitor, to fibrin. FXIII strengthens the fibrin clot by covalent bonds and protects fibrin from the prompt elimination by the fibrinolytic system. In the last two decades, FXIII has emerged as a key regulator of fibrinolysis. FXIII is also present in platelets, monocytes, and macrophages, but this cellular form does not contribute significantly to maintaining hemostasis. FXIII deficiency is a life-threatening bleeding diathesis whose clinical consequences are well studied. In contrast, the involvement of FXIII in thrombotic disorders and its association with the risk of such diseases are less clear. This review gives an account of the data accumulated mainly in the last decade on the association of FXIII with atherothrombotic diseases and presents conclusions and hypotheses drawn from these data as well as exposing the limitations of the published studies and our knowledge on this topic. The involvement of FXIII in atherogenesis, its role in coronary artery disease, atherothrombotic ischemic stroke, and peripheral artery disease are discussed, with particular reference to the association of FXIII levels and polymorphisms with the risk of these diseases.
Tárgyszavak:
Orvostudományok
Klinikai orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
Cardiovascular disease
factor XIII
factor XIII ploymorphisms
peripheral artery disease
stroke
Megjelenés:
Seminars in Thrombosis and Hemostasis. - 36 : 1 (2010), p. 018-033. -
További szerzők:
Bereczky Zsuzsanna (1974-) (orvosi laboratóriumi diagnosztika szakorvos)
Bagoly Zsuzsa (1978-) (orvos)
Shemirani, Amir-Houshang (1971-) (kutató orvos, laboratórium szakorvos)
Katona Éva (1961-) (klinikai biokémikus)
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
2.
001-es BibID:
BIBFORM103254
035-os BibID:
(cikkazonosító)1221 (WoS)000845794700001 (Scopus)85137397006
Első szerző:
Sadeghi, Farzaneh
Cím:
High Neutrophil-Lymphocyte Ratio and Low Lymphocyte-Monocyte Ratio Combination after Thrombolysis Is a Potential Predictor of Poor Functional Outcome of Acute Ischemic Stroke / Sadeghi Farzaneh, Sarkady Ferenc, Zsóri Katalin S., Szegedi István, Orbán-Kálmándi Rita, Székely Edina G., Vasas Nikolett, Berényi Ervin, Csiba László, Bagoly Zsuzsa, Shemirani Amir H.
Dátum:
2022
ISSN:
2075-4426
Megjegyzések:
(1) Background: Ischemic stroke is one of the leading causes of death and disability. An inflammatory response is observed in multiple stages of cerebral ischemia, particularly in the acute phase. Recent publications revealed that the neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) may be used to predict long-term prognosis in acute ischemic stroke (AIS) after thrombolysis. To test whether there is a relationship between the combination of these parameters and long-term prognosis, we analyzed the NLR-LMR combination in AIS patients treated with intravenous recombinant tissue plasminogen activator (rtPA); (2) Methods: The study included 285 adults with a diagnosis of AIS and rtPA treatment within a 4.5 h time window. Blood samples were obtained at admission and 24 h after thrombolysis to calculate pre- and post-thrombolysis NLR and LMR. Clinical data, including NIHSS was registered on admission and day 1. The long-term outcome was defined 90 days post-event by the modified Rankin Scale (mRS). Therapy-associated intracranial hemorrhage (ICH) was classified according to ECASS II. Receiver operating characteristic curve (ROC) analysis was performed to determine optimal cutoffs of NLR and LMR as predictors of therapy outcomes; (3) Results: Patients were stratified by cutoffs of 5.73 for NLR and 2.08 for LMR. The multivariate logistic regression model, including all possible confounders, displayed no significant association between NLR or LMR with 3-months functional prognosis. The combination of high NLR-low LMR vs. low NRL-high LMR as obtained 24 h after thrombolysis was found to be an independent predictor of poor 3-months functional outcome (mRS >= 2; OR 3.407, 95% CI 1.449 to 8.011, p = 0.005). The proportion of patients between low NLR-high LMR and high NLR-low LMR groups from admission to day 1 showed no significant change in the good outcome group. On the other hand, in the poor outcome group (mRS >= 2), low NLR-high LMR and high NLR-low LMR groups displayed a significant shift in patient proportions from 67% and 21% at admission (p = 0.001) to 36% and 49% at 24 h after thrombolysis (p < 0.001), respectively; (4) Conclusions: Our study demonstrated for the first time that a high NLR-low LMR combination as observed at 24 h after thrombolysis can serve as an independent predictor of 3-months poor outcome in AIS patients. This simple and readily available data may help clinicians to improve the prognostic estimation of patients and may provide guidance in selecting patients for personalized and intensified care post-thrombolysis.
Tárgyszavak:
Orvostudományok
Elméleti orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:
Journal of Personalized Medicine. - 12 : 8 (2022), p. 1-12. -
További szerzők:
Sarkady Ferenc (1982-) (laboratóriumi analitikus)
Zsóri Katalin Szilvia
Szegedi István (1969-) (hematológus, onkológus, nefrológus)
Orbán-Kálmándi Rita Angéla (1993-) (klinikai laboratóriumi kutató)
Székely Edina Gabriella
Molnárné Vasas Nikolett (1987-) (élettanász)
Berényi Ervin (1964-) (radiológus)
Csiba László (1952-) (neurológus, pszichiáter)
Bagoly Zsuzsa (1978-) (orvos)
Shemirani, Amir-Houshang (1971-) (kutató orvos, laboratórium szakorvos)
Pályázati támogatás:
GINOP-2.3.2-15-2016-00048
GINOP
Eötvös Loránd Kutatási Hálózat (ELKHDE Cerebrovascular and Neurodegenerative Research Group)
Egyéb
K120042
OTKA
FK128582
OTKA
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
3.
001-es BibID:
BIBFORM012809
Első szerző:
Shemirani, Amir-Houshang (kutató orvos, laboratórium szakorvos)
Cím:
The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma / Amir H. Shemirani, Gizella Haramura, Zsuzsa Bagoly, László Muszbek
Dátum:
2006
ISSN:
1570-9639
Megjegyzések:
The first step in the activation of blood coagulation factor XIII (FXIII) is the proteolytic cleavage of the potentially active A subunit (FXIII-A) by thrombin at Arg37-Gly38. Both fibrin formation and FXIII-AVal34Leu polymorphism influence the rate of proteolytic activation of purified factor XIII, however their relative importance and interaction in determining the time of onset and the rate of FXIII activation in whole plasma have not yet been explored. In the present study it was shown that in plasma, fibrin formation preceded the truncation of FXIII-A by thrombin, the activation process took place exclusively on the surface of newly formed fibrin and activated FXIII remained associated with the fibrin clot. The time of fibrin formation closely correlated with the time of FXIII activation, while there was no significant relationship between the time of FXIII activation and FXIII-AVal34Leu genotype. However, in the case of Leu34 variant the lag phase between fibrin formation and FXIII-A truncation was significantly shorter than in the case of Val34 variant. The results suggest that in whole plasma the onset of FXIII activation is determined by fibrin formation, while the rate of activation is modulated by Val34Leu polymorphism.
Tárgyszavak:
Orvostudományok
Elméleti orvostudományok
idegen nyelvű folyóiratközlemény külföldi lapban
Factor XIII Val34Leu polymorphism
Fibrinogen
Fibrin polymerization
Thrombin
Transglutaminase
Megjelenés:
Biochimica et Biophysica Acta (BBA). Proteins and Proteomics. - 1764 : 8 (2006), p. 1420-1423. -
További szerzők:
Haramura Gizella (1957-) (vezető analitikus)
Bagoly Zsuzsa (1978-) (orvos)
Muszbek László (1942-) (haematológus, kutató orvos)
Internet cím:
Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:
Rekordok letöltése
1
Corvina könyvtári katalógus v8.2.27
© 2023
Monguz kft.
Minden jog fenntartva.